Study compared women who continued on relugolix combination therapy with women who discontinued treatment
News
Cambridge start-up PhoreMost raises £33m to progress PLK1 programme
Lead ‘Allosteric PLK1’ asset will initially target brain cancer
UK Health Security Agency launches to address ‘future health threats’
New national agency will plan for, prevent and respond to external health threats including infectious diseases
AstraZeneca’s updated COVID-19 vaccine trial results show 76% efficacy
Initial results from US trial published earlier this week said the vaccine was 79% effective
Report urges pharma companies to utilise synthetic data in clinical trials
Report outlines two cases for using synthetic data in the clinical trial process
Zealand Pharma’s hypoglycaemia therapy Zegalogue scores approval in the US
Therapy authorised for the treatment of severe hypoglycaemia in people with diabetes
AZ to issue primary analysis for COVID-19 vaccine following ‘outdated information’ concerns
US data and safety monitoring board expressed ‘concern’ over initial trial data
FDA refuses Novo Nordisk’s once-weekly semaglutide
Company had been aiming for approval in type 2 diabetes
Roche ends tominersen study in manifest Huntington’s disease
Decision was based on the results of a pre-planned review of study data
Researchers identify molecular ‘cookie cutter’ technique for COVID-19 drug discovery
Researchers are aiming to isolate a stable form of the COVID-19 encounter complex
Daiichi Sankyo inks digital partnership for atrial fibrillation
Collaborative agreement will focus on improving detection and diagnosis of AF
AstraZeneca’s COVID-19 vaccine shows 79% efficacy in US trial
Jab was also found to have 100% efficacy at preventing severe disease and hospitalisation
FDA nod for Kiniksa’s Arcalyst in recurrent pericarditis
Recurrent pericarditis is an autoinflammatory cardiovascular disease
‘Formal review’ of GP access arrangements needed, says Healthwatch
UK-based charity conducted a review of GP access between April 2019 and December 2020
NICE recommends Kyprolis triple combination treatment for multiple myeloma
Kyprolis plus lenalidomide and dexamethasone approved as a second-line treatment
